The Penile Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Penile Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Penile Cancer. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Penile Cancer - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Penile Cancer and features dormant and discontinued products.

GlobalData tracks 47 drugs in development for Penile Cancer by 40 companies/universities/institutes. The top development phase for Penile Cancer is phase ii with 28 drugs in that stage. The Penile Cancer pipeline has 47 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Penile Cancer pipeline products market are: Merck, SQZ Biotechnologies and Dragonboat Biopharmaceutical (Shanghai).

The key targets in the Penile Cancer pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274), and Human Papillomavirus Protein E6 (E6).

The key mechanisms of action in the Penile Cancer pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with eight drugs in Phase II. The Penile Cancer pipeline products include 12 routes of administration with the top ROA being Intravenous and 11 key molecule types in the Penile Cancer pipeline products market including Monoclonal Antibody, and Small Molecule.

Penile Cancer overview

Penile cancer is a rare malignancy that develops on the skin or tissues of the penis. It occurs when normal cells in the penis undergo genetic mutations, leading to uncontrolled growth and the formation of a cancerous tumor. Early stages of penile cancer might not cause noticeable symptoms. As the disease progresses, signs and symptoms may include changes in skin color or texture of the penis; persistent growths or sores on the penis; redness, irritation, or ulceration on the penile skin; and pain, bleeding, discharge, or foul-smelling discharge from the penis.

For a complete picture of Penile Cancer’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.